SEFC
Spectrally encoded flow cytometry
| Coordinatore | TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY
Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie. |
| Nazionalità Coordinatore | Israel [IL] |
| Totale costo | 163˙680 € |
| EC contributo | 149˙848 € |
| Programma | FP7-IDEAS-ERC
Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | ERC-2011-PoC |
| Funding Scheme | CSA-SA(POC) |
| Anno di inizio | 2012 |
| Periodo (anno-mese-giorno) | 2012-07-01 - 2013-10-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
TECHNION - ISRAEL INSTITUTE OF TECHNOLOGY
Organization address
address: TECHNION CITY - SENATE BUILDING contact info |
IL (HAIFA) | hostInstitution | 149˙848.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'Measuring blood parameters noninvasively in patients is of great importance in many clinical applications. During the course of our research in an ERC-funded project, in which light is used to image and threat cancer, we have discovered that the minimally invasive imaging technique we have been developing, termed spectrally encoded endoscopy, is extremely effective for imaging flowing blood cells without the need for mechanical scanning. We have shown that this technique, termed spectrally encoded flow cytometry (SEFC), is capable of subsurface confocal imaging at sub-micron resolutions, at speeds that are sufficient for the detection of rapid capillary flow. Being able to image microscopic cellular features in patients without pain, stress, timely analysis and risk of infection, this technique represents an uncharted territory in medical diagnosis, and would have a wide variety of applications in routine care, intensive care and in the operating room. During the twelve months of the requested fund, we plan to complete a system prototype for future pre-clinical and clinical tests and establish a feasible business plan for further commercialization of the technology.'